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872 Abstracts March 2014major bleeds enrolled in ﬁve phase III trials comparing dabigatran with
warfarin in 27,419 patients treated for 6 to 36 months. There were 627
of 16,755 patients on dabigatran who had major bleeds. These patients
were older, had lower creatinine clearances, and more frequently used
aspirin or nonsteroid anti-inﬂammatory agents than those on warfarin
with major bleeds (n ¼ 407 of 10,002). Thirty-day mortality after the ﬁrst
major bleed tended to be lower in the dabigatran group (9.1%) than in the
warfarin group (13.0%; pooled odds ratio, 0.68; 95% conﬁdence interval,
0.46-1.01; P ¼ .057). With adjustments for sex, age, weight, renal function
and concomitant antithrombotic therapy, the pooled odds ratio for 30-day
mortality with dabigatran vs warfarin was 0.66 (95% conﬁdence interval,
0.144-1.00; P ¼ .051). In dabigatran patients with major bleeds, the
bleeding was more frequently treated with blood transfusions (61%) than
bleeds in warfarin patients (42%; P < .001). Patients with major bleeds
treated with dabigatran were less frequently treated with plasma compared
to warfarin patients with major bleeds (19.8% vs 30.2%; P < .001). Patients
with major bleeds had shorter stays in intensive care units if they had previ-
ously received dabigatran (mean,1.6 nights) compared with those who had
received warfarin (mean, 2.7 nights; P ¼ .01).
Comment: There is obviously no ideal anticoagulant agent. Despite
the fact there is no reversal agent for dabigatran, outcomes of major
bleeding on this drug appear no worse and are perhaps slightly better
than outcomes for patients with major bleeding on warfarin. It does not
appear overall resources needed to manage major bleeding on dabigatran
are greater than to manage such bleeding on warfarin. It also does not
appear that the prognosis after major bleeding is worse with dabigatran
than with warfarin despite the lack of a reversal agent for dabigatran. Dabi-
gatran is an alternative to warfarin with similar or superior efﬁcacy and over-
all lower risk of major bleeding. Bleeding episodes can be managed
satisfactorily with relatively simple measures such as drug discontinuation
and transfusion of red cells. Thus, the overall safety proﬁle of dabigatran
compared to warfarin remains favorable. Nevertheless, it is still desirable
to develop a speciﬁc antidote to dabigatran.
Effect of Smoking on Comparative Efﬁcacy of Antiplatelet Agents:
Systematic Review, Meta-Analysis, and Indirect Comparison
Gagne JJ, Bykov K, Choudhry NK, et al. BMJ 2013;347:f5307.
Conclusions: In randomized clinical trials of antiplatelet drugs, the
reported clinical beneﬁt of clopidogrel to reduce cardiovascular death,
myocardial infarction, and stroke is seen primarily in patients who smoke,
with little demonstrated beneﬁt in nonsmokers.
Summary: Recent subgroup analyses of randomized controlled trials
evaluating clopidogrel in cardiovascular disease have raised the question if
the efﬁcacy of the drug occurs primarily or exclusively among smokers
(Grubel PA et al, JAMA 2012;307:2495-6). Biochemically clopidogrel is
a prodrug. It requires a two-step metabolic activation process to attain
active form. Smoking induces cytochrome P450 isoenzyme 1 A2. This is
a key enzyme involved in the ﬁrst activation step of clopidogrel. It has
therefore been postulated that smoking increases the availability of clopi-
dogrel’s active metabolite, thereby enhancing its efﬁcacy. There are also
numerous antiplatelet agents such as prasugrel, also a prodrug but
requiring a less complex activation process than clopidogrel. Another
new antiplatelet agent, ticagrelor, is active by itself. In this paper, the au-
thors performed a systematic review, meta-analysis, and indirect compari-
sons to quantify the efﬁcacy of clopidogrel separately in smokers and
nonsmokers. They also sought to compare the efﬁcacy of newer antiplatelet
agents in these groups of patients. Data sources included Medline (1966-
present) and Embase (1974-present), along with supplementary searches
of databases of abstracts from major cardiology conferences. Also used
were the Index to Nursing and Allied Health (CINAHL), the CAB Ab-
stracts databases, and Google Scholar. Randomized trials of clopidogrel,
prasugrel, or ticagrelor that also examined clinical outcomes among sub-
groups of smokers and nonsmokers were identiﬁed. Two of the current au-
thors independently extracted all data, including information on patient
populations included in the trials, treatment types and doses, deﬁnitions
of clinical outcomes and duration of follow-up, deﬁnitions of smoking sub-
groups and number of patients in each group, and effect estimates with
95% conﬁdence intervals for each smoking status subgroup. There were
nine eligible randomized trials. One investigated clopidogrel compared
with aspirin, four investigated clopidogrel plus aspirin compared with
aspirin alone, and one investigated double dose clopidogrel compared
with standard dose clopidogrel. These trials included 74,489 patients of
whom 21,717 (29%) were smokers. Among smokers, those randomized
to clopidogrel, experienced a 25% reduction in the primary composite clin-
ical outcome of cardiovascular death, myocardial infarction, and stroke
compared with patients in the control group (relative risk [RR], 0.75;95% conﬁdence interval [CI], 0.67-0.83). There was just an 8% decrease
in nonsmokers in the composite outcome (RR, 0.92; 95% CI, 0.87-
0.98). There were two studies that investigated prasugrel plus aspirin
compared with clopidogrel plus aspirin, and one study investigated ticagre-
lor plus aspirin compared with clopidogrel plus aspirin. In smokers, the RR
was 0.71 (95% CI, 0.61-0.82) for prasugrel compared with clopidogrel and
0.83 (95% CI, 0.68-1.00) for ticagrelor compared with clopidogrel. Cor-
responding RRs among nonsmokers were 0.92 (95% CI, 0.83-1.01) and
0.89 (95% CI, 0.79-1.00).
Comment: The data suggest that clinicians may consider potential
beneﬁts and risks of antiplatelet drugs differently for those patients that
continue to smoke and those that do not. However, there is little under-
standing, or no understanding, of how the potential enhanced antiplatelet
effect in smokers might also increase the risk of bleeding. It will be impor-
tant to design future trials to determine whether different doses of clopidog-
rel should be used in smokers and nonsmokers to achieve clinical beneﬁt.
Electronic Cigarettes for Smoking Cessation: A Randomised
Controlled Trial
Bullen C, Howe C, Laugesen M, et al. Lancet 2013;382:1629-37.
Conclusions: Electronic cigarettes are associated with few adverse
events and, with or without nicotine, are modestly effective in aiding smok-
ing cessation. Results are similar to achievement of abstinence with nicotine
patches.
Summary: Electronic cigarettes were ﬁrst introduced in 2004. These
devices span a range of individual devices, many of which vaporize nicotine
for inhalation. Twenty-seven precent of patients making an attempt to quit
cigarettes in the UK have utilized electronic cigarettes (West R, July 20,
2012; http://www.smokinginengland.info/lastest-statistics/; accessed
August 9, 2013). It has been predicted that sales are increasing so rapidly
they will surpass actual cigarette sales within the decade (Purkayastha D;
http://www.thefreelibrary.com/;BAT Ramps-up E-cigarette Expansion
as Sales Go Up in Smoke). One trial, however, of 300 smokers demon-
strated low rates of cessation at 12 months for both nicotine e-cigarettes
and placebo e-cigarettes (Caponnetto P et al, PloS One 2013;8:e66317).
There is also controversy as to whether electronic cigarettes have the poten-
tial to produce harm (U.S. Food and Drug Administration; http://www.
fda.gov/NewsEvents/PublicHealthFocus/ucm173146.htm). This trial
sought to access whether electronic cigarettes with cartridges containing
nicotine were more effective for smoking cessation than nicotine patches.
There was also a blind comparison with electronic cigarettes containing
no nicotine (placebo e-cigarette). The hypothesis was that nicotine e-ciga-
rettes would be a more effective than patches and placebo e-cigarettes for
smoking reduction, tobacco dependence, and relief of withdrawal symptoms
and that there would be no greater risk of adverse events than with nicotine
patches. This was a randomized, controlled superiority trial from Aukland,
New Zealand conducted between September 6, 2011 and July 5, 2013.
Adult smokers ($18 years) wanting to quit were randomized and stratiﬁed
by ethnicity, sex, and level of nicotine dependence in a 4:4:1 ratio of 16-mg
nicotine e-cigarettes, nicotine patches (21 mg patch, one daily), or placebo
e-cigarettes (no nicotine), from 1 week before until 12 weeks after quit day.
There was also additional low intensity behavioral support via voluntary tele-
phone counseling. Primary outcome was biochemically veriﬁed continuous
abstinence at 6 months (exhaled breath carbon monoxide measurement
<10 ppm). Primary analysis was on an intention-to-treat basis. There
were 657 people randomized (289 to nicotine e-cigarettes, 295 to patches,
and 73 to placebo e-cigarettes) and who were included in the intention-to-
treat analysis. At 6 months, veriﬁed abstinence was 7.3% (21 of 289) with
nicotine e-cigarettes, 5.8 % (17 of 295) with patches, and 4.1% (3 of 73)
with placebo e-cigarettes. The risk difference for nicotine e-cigarettes vs
patches was 1.51 (95% conﬁdence interval, 2.49 to 5.51). Risk difference
for nicotine e-cigarettes vs placebo e-cigarettes was 3.16 (95% conﬁdence
interval, 2.29 to 8.61). Abstinence was substantially lower than anticipated
by prestudy power calculations.
Comment: Electronic cigarettes are big business. The study, howev-
er, would not suggest anything more than a very modest effect on absti-
nence rates through the use of electronic cigarettes. The authors found
that electronic cigarettes had higher acceptance rates among smokers
than other forms of nicotine replacement therapy. Since there were no dra-
matic differences in adverse events between other forms of nicotine
replacement therapy and electronic cigarettes, it may be possible, through
the design of more adequately powered trials, to demonstrate that elec-
tronic cigarettes can indeed have some potential for improving population
health. Currently, however, the data would not appear to support wide-
spread use of these devices if the goal is to have a signiﬁcant effect on
smoking cessation.
